Third, the complex crosstalk between HER2 and membranous ER may cause tamoxifen resistance.[16,20] Therefore, aromatase inhibitors, fulvestrant[20] and chemotherapy may be the most appropriate treatments for HER2-positive breast cancer. Here, CYP19A1 is linked to breast cancer.